Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nirmatrelvir→

Nirmatrelvir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2628280-40-8
Molecular formula
C23H32F3N5O4
Molecular weight
499.5 g/mol
Drug class
SARS-CoV-2 main protease (3CLpro/Mpro) inhibitorantiviral component of Paxlovid
Mechanism of action
Selectively inhibits the SARS-CoV-2 main protease (3CLpro/Mpro), preventing cleavage of viral polyproteins required for replication. It is administered with ritonavir, which inhibits CYP3A-mediated metabolism and increases nirmatrelvir exposure.
Indications / reported uses
  • In combination with ritonavir (PAXLOVID) for treatment of mild-to-moderate COVID-19 in adults at high risk for progression to severe disease, including hospitalisation or death, under the applicable product label; nirmatrelvir monotherapy is not the authorised regimen

Sources: US DailyMed — PAXLOVID (nirmatrelvir/ritonavir), label updated 2026 · US FDA — Paxlovid prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nirmatrelvir Environmental Risk Assessment (ERA) (the Nirmatrelvir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.